TauRx is committed to discovering and developing innovative therapies for neurodegenerative diseases caused by tau protein aggregation. Using leading-edge science and technology, TauRx is developing new treatments that are hoped to halt the progression of Alzheimer’s disease, frontotemporal dementia, and other neurodegenerative diseases.
Ultimately the company’s clinical aim is to make a positive difference to the lives of patients, carers and families who are affected by these devastating diseases.
Alzheimer's disease is a progressive neurologic disease of the brain that causes damage to neurons, leading to loss of memory and reasoning. It is the leading cause of dementia worldwide. The symptoms can affect a person’s ability to interact socially or function at work. No treatment currently exists that either halts the progression of Alzheimer’s related dementia or delays its onset, or better yet, prevents it from occurring. The available drugs treat the symptoms, but only temporarily. An Alzheimer’s treatment that can effectively halt or delay disease progression is urgently needed.
A potential way to halt or delay Alzheimer’s disease is by preventing the aggregation of tau protein to form tangles, which are closely linked to the dementia seen in Alzheimer’s disease. Tau tangles form inside brain cells when tau protein begins to aggregate, ultimately causing brain cell death. TauRx has developed a second-generation tau aggregation inhibitor which recently completed two Phase 3 clinical trials for Alzheimer's disease.
Frontotemporal dementia (FTD) is a degenerative disease that causes gradual and progressive damage to the frontal and temporal regions of the brain. These areas of the brain are responsible for behaviour and language. FTD often develops at a relatively young age (40s to 60s). As the disease progresses, patients can find it difficult to plan or organise activities, behave appropriately in social or work settings, interact with others, and care for themselves, resulting in increasing dependency on others. FTD-associated syndromes are responsible for about 10% of all dementia. Currently no treatments to slow or stop the progression of the disease are available.
A type of FTD called behavioural variant FTD (bvFTD) can cause early and progressive changes in personality, emotional ‘blunting’ and loss of empathy. A person with bvFTD may have difficulty controlling their behaviour, which can result in socially inappropriate responses or actions. Language may also be impaired after behavioural changes take place and neurological symptoms such as movement and coordination difficulties may develop. Over time, these symptoms worsen. The bvFTD form of the disease is particularly aggressive and progresses faster than Alzheimer’s disease.
TauRx has recently completed a Phase 3 clinical study to evaluate the safety and efficacy of LMTX® in patients with bvFTD.